DoD Prostate Cancer, Health Disparity Research Award | W81XWH 21 PCRP HDRA

Opportunity Information: Apply for W81XWH 21 PCRP HDRA

The DoD Prostate Cancer Research Program (PCRP) Health Disparity Research Award (FY21; opportunity number W81XWH-21-PCRP-HDR A) is a Department of Defense funding opportunity meant to back research ideas that can materially reduce prostate cancer health disparities. The core goal is to eliminate inequities in prostate cancer incidence, morbidity, mortality, and survivorship by supporting projects that can produce meaningful, actionable advances rather than incremental findings. Proposals are expected to clearly align with one or more of the FY21 award Focus Areas and to explain, in plain terms, how the work will address a disparity-related problem. If a project does not neatly fit a listed Focus Area, it can still be competitive, but the applicant must justify why the project addresses an urgent disparity-related need in the context of the PCRP Overarching Challenges.

The program is intentionally broad about what kinds of science it will support. It welcomes a wide range of disciplines, including basic biology, engineering and technology development, bioinformatics and data science, population science and epidemiology, psycho-oncology, translational research, and health services or care-delivery research. Projects can be basic, translational, or clinical, and clinical trials are allowed with an important limitation: only small-scale, early-stage trials up through Phase 2 (or equivalent) are supported under this mechanism. Investigators who propose trials are encouraged to leverage the Prostate Cancer Clinical Trials Consortium (PCCTC) to speed start-up and execution. Preliminary data are encouraged but not required, and any unpublished preliminary results included should come from the PI or members of the research team.

A recurring theme in this award is community engagement and real-world relevance. Applicants are strongly encouraged to involve members of the affected population or community in shaping and carrying out the research when that makes sense for the project. If population- or community-based organizations will be used to recruit, advise, implement, or disseminate, that involvement should be concrete and documented through letters of support that spell out roles and commitments. The opportunity materials also point applicants toward a large set of potential resources and partners, such as the North Carolina-Louisiana Prostate Cancer Project (PCaP) biorepository, NIH and NCI health disparity networks, community-based participatory research programs, and advocacy organizations that work with disproportionately affected groups (including organizations focused on rural health and LGBT cancer equity).

The award also puts heavy weight on impact, innovation, and what happens after the project ends. Applicants are expected to propose work with a credible path to significantly addressing prostate cancer disparities, and higher innovation is viewed as a driver of larger potential impact. A required element is a detailed transition plan that explains how findings will move into the next stage of development after the award period, so the work keeps advancing toward clinical or public health impact even if immediate clinical change is not the endpoint of the funded aims. In practice, this means reviewers are looking for a strong story about follow-on validation, scale-up, implementation, regulatory steps, or subsequent trial planning.

Methodological rigor is treated as non-negotiable, particularly in disparity research where population definitions and study design decisions can strongly influence conclusions. For projects examining biological contributors to disparities across populations, applicants are explicitly asked to think carefully about how they stratify groups, including the implications of using genetic/genomic classification versus self-reported race, and to justify the chosen approach. Applications must include a robust statistical plan and a complete power analysis demonstrating that the sample size and analytic approach can actually answer the question posed. The announcement also encourages specific best practices that strengthen reproducibility and translational value, such as authenticating proposed cell lines, ensuring statistical rigor in animal studies (for example, randomization, blinding, and appropriate sample size estimation), and including experiments that test clinical relevance and translatability. Where specialized resources are essential (datasets, samples, facilities, models, or partner sites), applicants are encouraged to document access and availability with letters of support.

A dedicated New Investigator category is included to bring early-career researchers into prostate cancer disparity work. Under this track, early-stage faculty or investigators building independence can serve as PI, but they must include at least one experienced collaborator with a demonstrated track record in prostate cancer health disparity research (funding and publications). The application must explain why the collaboration is likely to work, what each party contributes, and how the partner(s) will strengthen the PI’s ability to address the question. Letters of collaboration are strongly encouraged to clarify the collaborator’s role, level of effort, and concrete responsibilities.

From an administrative and award-structure standpoint, awards are issued as assistance agreements, meaning they can be either grants or cooperative agreements depending on the anticipated level of DoD involvement during performance. If the agency expects no substantial involvement, a grant is used; if substantial involvement is anticipated (such as active collaboration, participation, or other intervention by the funder), a cooperative agreement is used, and the specific involvement is spelled out in the award. The opportunity emphasizes relevance to active-duty Service Members, Veterans, military beneficiaries, and/or the broader American public, and it encourages collaborations between military or VA institutions and civilian organizations to combine infrastructure, expertise, and access to unique patient populations.

The funding profile described for this cycle anticipates a direct cost cap of up to $750,000 over the full period of performance. Program-wide, CDMRP expected to allocate about $10.8 million to support roughly nine awards. Awards were expected to be made by September 30, 2022, and the FY21 funds associated with these awards were expected to remain available for use until September 30, 2027, reflecting the limited life of the appropriation. Eligibility is described as unrestricted (open to many organization types), subject to any clarifications in the full announcement.

Finally, the award carries the standard DoD human and animal research compliance requirements, which can meaningfully affect timelines. Human subjects research (including work with human anatomical substances or cadavers) requires review not only by a local IRB or ethics committee, but also by the USAMRDC Human Research Protection Office (HRPO) before research begins, and applicants are told to plan for roughly 2 to 3 months for that additional regulatory review. For multi-institution human studies, a plan for a single IRB arrangement is required, including identification of the lead institution responsible for the master protocol and consent materials. Animal studies similarly require review by both the local IACUC and the USAMRDC Animal Care and Use Review Office (ACURO), with an expected additional review window of about 3 to 4 months. For funded clinical trials, there is also a requirement to post the IRB-approved informed consent form on a public federal website consistent with 32 CFR 219. If investigators intend to use DoD or VA populations, databases, or other resources, the application must describe access plans up front and how access will be maintained through the project period.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Prostate Cancer, Health Disparity Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 05, 2021.
• Applicants must submit their applications by Jul 29, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 9 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 PCRP HDRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: